Redhill Biopharma Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Redhill Biopharma Ltd., a foreign private issuer based in Tel Aviv, Israel, for the month of May 2019. The filing date is May 28, 2019. The report incorporates by reference a press release announcing a key executive appointment.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a corporate event rather than a financial statement.
Material Changes
The primary material change disclosed is the appointment of Dr. June Almenoff as the Company's Chief Scientific Officer.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, outlook, management commentary on operations, specific risks, contingencies, or unusual items beyond the executive appointment.
Key Facts for Investor Verification
- Dr. June Almenoff has been appointed as Chief Scientific Officer.
- The filing incorporates a press release dated May 28, 2019, regarding this appointment.
- No financial performance data is included in this specific Form 6-K.